Moderna Stock Plunges Despite ‘Vaccine Day’ Touting 31 New Shots And $21 Billion In Sales—Here’s Why |
| March 26, 2022 | March 2022 Bond Updates |
|
One analyst blasted Moderna’s flu vaccine results as a “nonstarter” clinically, while others said investors are still too focused on Covid. |
| View more at: https://www.forbes.com/sites/jonathanponciano/2022/03/25/moderna-stock-mrna-plunges-despite-vaccine-day-touting-31-new-shots-and-21-billion-in-sales-heres-why/ |